Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery
- PMID: 34392175
- DOI: 10.1016/j.bioorg.2021.105242
Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery
Abstract
Enoyl acyl carrier protein reductase (InhA) is a key enzyme involved in fatty acid synthesis mainly mycolic acid biosynthesis that is a part of NADH dependent acyl carrier protein reductase family. The aim of the present literature is to underline the different scaffolds or enzyme inhibitors that inhibit mycolic acid biosynthesis mainly cell wall synthesis by inhibiting enzyme InhA. Various scaffolds were identified based on the screening technologies like high throughput screening, encoded library technology, fragment-based screening. The compounds studied include indirect inhibitors (Isoniazid, Ethionamide, Prothionamide) and direct inhibitors (Triclosan/Diphenyl ethers, Pyrrolidine Carboxamides, Pyrroles, Acetamides, Thiadiazoles, Triazoles) with better efficacy against drug resistance. Out of the several scaffolds studied, pyrrolidine carboxamides were found to be the best molecules targeting InhA having good bioavailability properties and better MIC. This review provides with a detailed information, analysis, structure activity relationship and useful insight on various scaffolds as InhA inhibitors.
Keywords: Enoyl acyl carrier protein reductase (InhA); INH-NAD adduct; Kat G; Multi-drug resistant TB; Tuberculosis.
Copyright © 2021. Published by Elsevier Inc.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
